{"id":"W2244807134","doi":"10.1200/jco.2006.24.18_suppl.5018","title":"Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: Preliminary results of a multi-center phase II trial","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Gastroenterology; Ovarian cancer; Erlotinib; Refractory (planetary science); Phases of clinical research; Vascular endothelial growth factor; Cancer; Urology; Chemotherapy; Surgery; Epidermal growth factor receptor; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001183997,0.0008785647,0.001032148,0.0002892927,0.0002562831,0.0007541846,0.0004866391,0.000810604,0.001798065],"category_scores_gemma":[0.0007265803,0.0003083016,0.0008180037,0.0003704429,0.0004065436,0.0006079348,0.0002650596,0.001726646,0.0003807627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000705038,"about_ca_system_score_gemma":0.000930489,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001239746,"about_ca_topic_score_gemma":0.003929955,"domain_scores_codex":[0.9997665,0.0001207557,0.00001688593,0.00003392288,0.00001876858,0.00004311842],"domain_scores_gemma":[0.9995447,0.00008263834,0.00007810904,0.00002042799,0.00002354572,0.000250466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7111213,0.03021924,0.0132798,0.001357701,0.001642752,0.0006003379,0.0003925971,0.003382211,0.03407857,0.0002182987,0.006014623,0.1976927],"study_design_scores_gemma":[0.6441713,0.3204865,0.02621811,0.00009199051,0.0005867027,0.0005454019,0.00007973379,0.002195321,0.002117489,0.000164555,0.003311392,0.00003148203],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942725,0.002539454,0.0002410578,0.0004196983,0.00006526693,0.0009256379,0.0004450129,0.00004999014,0.001041434],"genre_scores_gemma":[0.9920409,0.002286754,0.001097433,0.0006976624,0.0001258579,0.001047365,0.001334231,0.00001592106,0.001353898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001798065,"threshold_uncertainty_score":0.006261647,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1005680349449474,"score_gpt":0.4501131593538547,"score_spread":0.3495451244089073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}